Stroke; a journal of cerebral circulation
-
Randomized Controlled Trial Multicenter Study
The VASOGRADE: A Simple Grading Scale for Prediction of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.
Patients are classically at risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage. We validated a grading scale-the VASOGRADE-for prediction of DCI. ⋯ The VASOGRADE results validated previously published risk charts in a large and diverse sample of subarachnoid hemorrhage patients, which allows DCI risk stratification on presentation after subarachnoid hemorrhage. It could help to select patients at high risk of DCI, as well as standardize treatment protocols and research studies.
-
Randomized Controlled Trial Multicenter Study
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial.
Randomized trials have indicated a benefit for endovascular therapy in appropriately selected stroke patients at 3 months, but data regarding outcomes at 12 months are currently lacking. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
-
Randomized Controlled Trial Multicenter Study
Acupuncture efficacy on ischemic stroke recovery: multicenter randomized controlled trial in China.
Acupuncture is a frequently used complementary treatment for ischemic stroke in China but the evidence available from previous randomized trials is inconclusive. The objective of this study was to assess the efficacy and safety of acupuncture in a more robustly designed larger scale trial. ⋯ URL: http://www.chictr.org/en/. Unique identifier: ChiCTR-TRC-11001353.
-
Randomized Controlled Trial Multicenter Study
Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the intensive blood pressure reduction in acute cerebral hemorrhage trial studies.
Controversy exists over the prognostic significance of perihematomal edema (PHE) in intracerebral hemorrhage. We aimed to determine the association of early PHE and clinical outcome among participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT) studies. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.
-
Multicenter Study Clinical Trial
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01654445.